Since its approval by the FDA in 2013, Belviq® has been used to successfully treat patients with obesity by acting on serotonin receptors in the brain to increase feelings of satiety. However, the drug was recently used in studies at the University of Texas on rhesus monkeys who were addicted to cocaine, as the addiction/reward pathway is closely related to serotonin and dopamine. Results showed that the monkeys who had taken the anti-obesity drug experienced a decreased response rate for self-injection of cocaine. This held true even in large cocaine doses. Investigations are moving toward human trials, and researchers are looking into the effects of Belviq® on methamphetamine addiction.